FitLife Brands (FTLF) Competitors

$10.07 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$10.06 -0.01 (-0.05%)

As of 05/22/2026 04:10 PM Eastern

FTLF vs. CMPX, GLSI, IMRX, ORGO, and SRZN

Should you buy FitLife Brands stock or one of its competitors? MarketBeat compares FitLife Brands with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FitLife Brands include Compass Therapeutics (CMPX), Greenwich LifeSciences (GLSI), Immuneering (IMRX), Organogenesis (ORGO), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry.

How does FitLife Brands compare to Compass Therapeutics?

FitLife Brands (NASDAQ:FTLF) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

FitLife Brands presently has a consensus target price of $21.50, suggesting a potential upside of 113.51%. Compass Therapeutics has a consensus target price of $13.60, suggesting a potential upside of 557.00%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

FitLife Brands has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.16	$6.33M	$0.60	16.78
Compass Therapeutics	$850K	438.57	-$66.49M	-$0.41	N/A

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 61.4% of FitLife Brands shares are held by insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

FitLife Brands has a net margin of 6.64% compared to Compass Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Compass Therapeutics	N/A	-39.75%	-35.29%

FitLife Brands has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

In the previous week, Compass Therapeutics had 6 more articles in the media than FitLife Brands. MarketBeat recorded 7 mentions for Compass Therapeutics and 1 mentions for FitLife Brands. Compass Therapeutics' average media sentiment score of 0.28 beat FitLife Brands' score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FitLife Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Compass Therapeutics beats FitLife Brands on 9 of the 17 factors compared between the two stocks.

How does FitLife Brands compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Greenwich LifeSciences presently has a consensus target price of $47.50, indicating a potential upside of 71.79%. FitLife Brands has a consensus target price of $21.50, indicating a potential upside of 113.51%. Given FitLife Brands' higher possible upside, analysts plainly believe FitLife Brands is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Greenwich LifeSciences had 1 more articles in the media than FitLife Brands. MarketBeat recorded 2 mentions for Greenwich LifeSciences and 1 mentions for FitLife Brands. Greenwich LifeSciences' average media sentiment score of 0.00 equaled FitLife Brands'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
FitLife Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 61.4% of FitLife Brands shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Greenwich LifeSciences has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, FitLife Brands has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

FitLife Brands has a net margin of 6.64% compared to Greenwich LifeSciences' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%
FitLife Brands	6.64%	18.31%	8.21%

FitLife Brands has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A
FitLife Brands	$81.46M	1.16	$6.33M	$0.60	16.78

Summary

FitLife Brands beats Greenwich LifeSciences on 9 of the 13 factors compared between the two stocks.

How does FitLife Brands compare to Immuneering?

Immuneering (NASDAQ:IMRX) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

In the previous week, Immuneering had 3 more articles in the media than FitLife Brands. MarketBeat recorded 4 mentions for Immuneering and 1 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 0.00 beat Immuneering's score of -0.14 indicating that FitLife Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
FitLife Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

FitLife Brands has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
FitLife Brands	$81.46M	1.16	$6.33M	$0.60	16.78

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 61.4% of FitLife Brands shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Immuneering has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, FitLife Brands has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

Immuneering presently has a consensus price target of $16.50, indicating a potential upside of 206.12%. FitLife Brands has a consensus price target of $21.50, indicating a potential upside of 113.51%. Given Immuneering's stronger consensus rating and higher probable upside, research analysts clearly believe Immuneering is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

FitLife Brands has a net margin of 6.64% compared to Immuneering's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
FitLife Brands	6.64%	18.31%	8.21%

Summary

FitLife Brands beats Immuneering on 9 of the 16 factors compared between the two stocks.

How does FitLife Brands compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

FitLife Brands has a net margin of 6.64% compared to Organogenesis' net margin of -0.84%. FitLife Brands' return on equity of 18.31% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
FitLife Brands	6.64%	18.31%	8.21%

In the previous week, Organogenesis had 1 more articles in the media than FitLife Brands. MarketBeat recorded 2 mentions for Organogenesis and 1 mentions for FitLife Brands. Organogenesis' average media sentiment score of 0.37 beat FitLife Brands' score of 0.00 indicating that Organogenesis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
FitLife Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organogenesis currently has a consensus target price of $8.50, indicating a potential upside of 219.55%. FitLife Brands has a consensus target price of $21.50, indicating a potential upside of 113.51%. Given Organogenesis' higher probable upside, analysts clearly believe Organogenesis is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Organogenesis has higher revenue and earnings than FitLife Brands. Organogenesis is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.61	$37.03M	-$0.19	N/A
FitLife Brands	$81.46M	1.16	$6.33M	$0.60	16.78

Organogenesis has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, FitLife Brands has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 33.0% of Organogenesis shares are owned by insiders. Comparatively, 61.4% of FitLife Brands shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

FitLife Brands beats Organogenesis on 9 of the 16 factors compared between the two stocks.

How does FitLife Brands compare to Surrozen?

FitLife Brands (NASDAQ:FTLF) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 61.4% of FitLife Brands shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

FitLife Brands currently has a consensus price target of $21.50, indicating a potential upside of 113.51%. Surrozen has a consensus price target of $42.00, indicating a potential upside of 59.27%. Given FitLife Brands' higher possible upside, equities analysts clearly believe FitLife Brands is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

FitLife Brands has a net margin of 6.64% compared to Surrozen's net margin of -4,810.50%. FitLife Brands' return on equity of 18.31% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

In the previous week, FitLife Brands and FitLife Brands both had 1 articles in the media. FitLife Brands' average media sentiment score of 0.00 equaled Surrozen'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FitLife Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Surrozen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

FitLife Brands has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.16	$6.33M	$0.60	16.78
Surrozen	$3.48M	87.98	-$242.03M	-$37.59	N/A

FitLife Brands has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Summary

FitLife Brands beats Surrozen on 9 of the 15 factors compared between the two stocks.

Get FitLife Brands News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTLF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTLF vs. The Competition

Export

Metric	FitLife Brands	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$94.57M	$8.52B	$6.46B	$12.34B
Dividend Yield	N/A	2.50%	2.76%	5.28%
P/E Ratio	16.67	16.24	21.21	25.65
Price / Sales	1.16	8.28	554.38	86.31
Price / Cash	8.64	17.11	43.49	56.67
Price / Book	2.08	4.06	10.37	7.14
Net Income	$6.33M	$224.05M	$3.57B	$335.98M
7 Day Performance	0.70%	5.34%	6.40%	4.15%
1 Month Performance	7.36%	-0.08%	3.53%	2.54%
1 Year Performance	-30.93%	0.98%	34.04%	35.06%

FitLife Brands Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTLF FitLife Brands	4.1818 of 5 stars	$10.07 flat	$21.50 +113.5%	-30.9%	$94.57M	$81.46M	16.67	20	Gap Up
CMPX Compass Therapeutics	3.2272 of 5 stars	$1.97 +5.3%	$13.60 +590.4%	-1.0%	$354.77M	N/A	N/A	20
GLSI Greenwich LifeSciences	1.1652 of 5 stars	$25.30 +2.4%	$47.50 +87.7%	+181.9%	$350.41M	N/A	N/A	3
IMRX Immuneering	2.1702 of 5 stars	$5.38 +3.9%	$16.50 +206.7%	+250.0%	$348.07M	N/A	N/A	60
ORGO Organogenesis	2.4209 of 5 stars	$2.70 +12.0%	$8.50 +214.8%	-8.3%	$347.44M	$564.17M	N/A	950

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTLF) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FitLife Brands (FTLF) Competitors

FTLF vs. CMPX, GLSI, IMRX, ORGO, and SRZN

How does FitLife Brands compare to Compass Therapeutics?

Summary

How does FitLife Brands compare to Greenwich LifeSciences?

Summary

How does FitLife Brands compare to Immuneering?

Summary

How does FitLife Brands compare to Organogenesis?

Summary

How does FitLife Brands compare to Surrozen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTLF vs. The Competition

FitLife Brands Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FitLife Brands (FTLF) Competitors

FTLF vs. CMPX, GLSI, IMRX, ORGO, and SRZN

How does FitLife Brands compare to Compass Therapeutics?

Do analysts prefer FTLF or CMPX?

Which has better earnings & valuation, FTLF or CMPX?

Do insiders & institutionals believe in FTLF or CMPX?

Is FTLF or CMPX more profitable?

Which has more volatility & risk, FTLF or CMPX?

Does the media favor FTLF or CMPX?

Summary

How does FitLife Brands compare to Greenwich LifeSciences?

Do analysts recommend GLSI or FTLF?

Does the media refer more to GLSI or FTLF?

Do institutionals & insiders believe in GLSI or FTLF?

Which has more risk and volatility, GLSI or FTLF?

Is GLSI or FTLF more profitable?

Which has stronger valuation & earnings, GLSI or FTLF?

Summary

How does FitLife Brands compare to Immuneering?

Does the media refer more to IMRX or FTLF?

Which has better valuation & earnings, IMRX or FTLF?

Do insiders and institutionals believe in IMRX or FTLF?

Which has more risk and volatility, IMRX or FTLF?

Do analysts rate IMRX or FTLF?

Is IMRX or FTLF more profitable?

Summary

How does FitLife Brands compare to Organogenesis?

Is ORGO or FTLF more profitable?

Does the media refer more to ORGO or FTLF?

Do analysts rate ORGO or FTLF?

Which has higher earnings and valuation, ORGO or FTLF?

Which has more risk & volatility, ORGO or FTLF?

Do insiders & institutionals believe in ORGO or FTLF?

Summary

How does FitLife Brands compare to Surrozen?

Do institutionals and insiders believe in FTLF or SRZN?

Do analysts recommend FTLF or SRZN?

Is FTLF or SRZN more profitable?

Does the media prefer FTLF or SRZN?

Which has stronger valuation & earnings, FTLF or SRZN?

Which has more volatility and risk, FTLF or SRZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTLF vs. The Competition

FitLife Brands Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools